'Pfizer Halts Work On Hemophilia Gene Therapy; U.S. Drugmaker To Focus On Different Treatment For Disorder, Citing Low Interest' - Nikkei Asia
PFEFebruary 20, 2025
Read more →What's Driving the Market Sentiment Around Pfizer?
PFEPfizer's (NYSE:PFE) short percent of float has fallen 19.75% since its last report. The company recently reported that it has 73.57 million shares sold short, which is 1.3% of all regular shares that are available for trading.
February 20, 2025
Read more →Pfizer's Talzenna/Xtandi Combo Improves Survival Outcomes In Metastatic Castration-Resistant Prostate Cancer
PFEPfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS gain in HRR-mutated cases.
February 14, 2025
Read more →Pfizer Announces Phase 3 TALAPRO-2 Study Results: TALZENNA + XTANDI Shows Significant OS Improvement In mCRPC Patients; 9-Month OS Gain In Unselected Paitents, 14-Month In Paitents Selected For HRR Mutations, Secondary Endpoint Met; To Be Presented at ASC
PFEFebruary 13, 2025
Read more →U.S. FDA Approves Pfizer's ADCETRIS Combination Regimen For The Treatment Of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
PFEFebruary 12, 2025
Read more →Reported Feb 11, 2025 FDA Approves Brentuximab Vedotin With Lenalidomide And Rituximab For Relapsed Or Refractory Large B-Cell Lymphoma
PFEFebruary 12, 2025
Read more →Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent Cliff Challenges
PFEPfizer CEO highlights savings, leadership changes, and acquisition-driven growth amid significant revenue loss challenges projected by 2026-2028.
January 14, 2025
Read more →Pfizer CEO Albert Bourla Says Looking At Everything In The Obesity Market Beyond Injectable GLP-1 Drugs; Says All In On Obesity Drug Development
PFEJanuary 13, 2025
Read more →A Closer Look at Pfizer's Options Market Dynamics
PFEJanuary 13, 2025
Read more →Pfizer Reveals Encouraging Data From Pivotal Bladder Cancer Trial
PFEPfizer's Phase 3 CREST trial results highlight the efficacy of sasanlimab combined with BCG in treating high-risk non-muscle invasive bladder cancer.
January 10, 2025
Read more →Pfizer Says Its Sasanlimab In Combination With Bacillus Calmette-Guérin (BCG) Improves Event-Free Survival In Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
PFEJanuary 10, 2025
Read more →This Is What Whales Are Betting On Pfizer
PFEDecember 23, 2024
Read more →FDA Grants Accelerated Approval To Encorafenib With Cetuximab And mFOLFOX6 For Metastatic Colorectal Cancer With A BRAF V600E Mutation
PFEDecember 20, 2024
Read more →UK Tribunal Fines Pfizer And Flynn £69M For Excessive Pricing Of Epilepsy Drug, Finds Firms Abused Dominant Market Positions From 2012-2016
PFENovember 20, 2024
Read more →Pfizer Announced That The European Commission Has Granted Marketing Authorization For Hympavzi (marstacimab) For Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors
PFENovember 20, 2024
Read more →Stock Of The Day: Is Pfizer Set Up To Rally?
PFEShares of Pfizer (PFE) may be about to reverse and head higher. They are both oversold and at a support level.
November 15, 2024
Read more →Unpacking the Latest Options Trading Trends in Pfizer
PFENovember 15, 2024
Read more →Key Takeaways From Pfizer Analyst Ratings
PFENovember 15, 2024
Read more →Wolfe Research Initiates Coverage On Pfizer with Underperform Rating, Announces Price Target of $25
PFENovember 15, 2024
Read more →Peering Into Pfizer's Recent Short Interest
PFENovember 5, 2024
Read more →Pfizer Says In Q2 2024, It Is Launching A Multi-Tear Program To Reduce Our Cost Of Goods Sold; First Phase Of Multi-Year Program To Reduce Cost Of Goods Sold Is Expected To Deliver Savings Of ~$1.5B By End Of 2027; Costs Will Be Recorded Primarily In 2024
PFEMay 22, 2024
Read more →Market Whales and Their Recent Bets on PFE Options
PFEMay 22, 2024
Read more →Hospira Inc. Issues A Voluntary Nationwide Recall For Buprenorphine Hydrochloride Injection Carpuject™ Units and Labetalol Hydrochloride Injection, USP Carpuject™ Units Due To The Potential For Incomplete Crimp Seals - Press Release
PFEMay 21, 2024
Read more →Pfizer Unusual Options Activity
PFEMay 20, 2024
Read more →Pfizer Disappointed About 1st Instance Decision By Opposition Division Of European Patent Office To Maintain Moderna's European Patent Ep3590949 B1; Says Will Consider All Legal Options And May Appeal Decision By European Patent Office
PFEMay 17, 2024
Read more →Spotlight on Pfizer: Analyzing the Surge in Options Activity
PFEMay 16, 2024
Read more →Pfizer Settles Zantac Lawsuits, Agrees To $250M Settlement To Reduce Liability: Report
PFEIn a bid to settle thousands of lawsuits over its discontinued heartburn drug Zantac, Pfizer Inc has agreed to pay up to $250 million.
May 16, 2024
Read more →Pfizer Initiates Phase 3 Study Of mRNA-Based Influenza Vaccine
PFESeptember 14, 2022
Read more →Strata Oncology Announces Expansion Of Clinical Collaboration With Pfizer For Strata PATH Trial Into Early-Stage Cancer
PFESeptember 13, 2022
Read more →Japan's Health Ministry Approves Pfizer Covid-19 Vaccine Targeting Omicron Variant
PFESeptember 12, 2022
Read more →Check Out What Whales Are Doing With PFE
PFEA whale with a lot of money to spend has taken a noticeably bearish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 17 strange trades.
September 9, 2022
Read more →U.S. FDA And European Medicines Agency Accepted Pfizer's Hair Loss Candidate Submission For Review
PFEThe U.S. Food and Drug Administration (FDA) has accepted for review Pfizer’s (NYSE: PFE) New Drug Application (NDA) for ritlecitinib for adults and adolescents 12 years of age and older with alopecia areata. The regulatory agency is expected to make a decision in the second-quarter of 2023.
September 9, 2022
Read more →FDA And EMA Accept Regulatory Submission For Pfizer's Ritlecitinib For Individuals 12 Years And Older With Alopecia Areata
PFESeptember 9, 2022
Read more →4 Analysts Have This to Say About Pfizer
PFEWithin the last quarter, Pfizer (NYSE:PFE) has observed the following analyst ratings:
May 4, 2022
Read more →Morgan Stanley Maintains Equal-Weight on Pfizer, Lowers Price Target to $52
PFEMay 4, 2022
Read more →Wells Fargo Maintains Overweight on Pfizer, Lowers Price Target to $55
PFEMay 4, 2022
Read more →Pfizer Highlights Presentation Of Evidence Showing Associated Benefits For Patients Treated With Co.'s IBRANCE In Combo With Aromatase Inhibitor At European Society For Medical Oncology May 4, 2022
PFEMay 4, 2022
Read more →Pfizer Stock Flies Higher Following Q1 Earnings Print: Here's What To Watch For Next
PFEPfizer, Inc (NYSE: PFE) shot up over 3% on Tuesday after printing its first-quarter earnings before the market open.
May 3, 2022
Read more →Pfizer Posts Street Beating Q1 Earnings, Revises FY22 Profit Outlook
PFEMay 3, 2022
Read more →Pfizer: Q1 Earnings Insights
PFEPfizer (NYSE:PFE) reported its Q1 earnings results on Tuesday, May 3, 2022 at 06:45 AM. Here's what investors need to know about the announcement. Earnings Pfizer beat estimated earnings by 8.0%, reporting an EPS of $1.62 versus an estimate of $1.5.
May 3, 2022
Read more →Pfizer Revises FY22 Adj. EPS Guidance To $6.25-$6.45 To Reflect $0.11 Negative Impact For Accounting Policy Change; Sees Sales $98B-$102B vs $107.94B Est.
PFEMay 3, 2022
Read more →Pfizer Q1 Adj. EPS $1.62 Beats $1.50 Estimate, Sales $25.70B Beat $23.95B Estimate
PFEMay 3, 2022
Read more →Check Out What Whales Are Doing With PFE
PFEA whale with a lot of money to spend has taken a noticeably bearish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 16 strange trades.
May 2, 2022
Read more →Pfizer's COVID-19 Antiviral Pill Fails To Prevent Post Exposure Infection In Household Members
PFEMay 2, 2022
Read more →Pfizer Shares Top-Line Results From Phase 2/3 EPIC-PEP Study Of PAXLOVIDTM For Post-Exposure Prophylactic Use; Says Results Of Study Were Not Statistically Significant
PFEApril 29, 2022
Read more →This Is What Whales Are Betting On Pfizer
PFEA whale with a lot of money to spend has taken a noticeably bearish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 17 strange trades.
April 29, 2022
Read more →Fauci Says There Is Anecdotal Evidence Of Some People Taking Pfizer's Oral Drug Paxlovid Have Shown Rebound In Either Test Positivity Or Mild Symptoms
PFEApril 29, 2022
Read more →FDA Gives Green Signal To Pfizer's Duchenne Gene Therapy Trial
PFEApril 28, 2022
Read more →